Cardiorenal syndrome: when heart and kidney disease interact

Heart and kidney disease together produce some of the most challenging clinical situations I deal with. Treatment for one organ can worsen the other. Decisions involve careful balancing. This article sets out how I approach cardiorenal syndrome in clinic and the modern treatment combinations that have changed the picture.

When heart and kidney disease occur together, they do not exist as separate problems. They interact. Each places strain on the other. Treatments for one can worsen the other. The combination produces clinical challenges that neither cardiology nor nephrology can address well in isolation. The term cardiorenal syndrome describes these interactions, and understanding it is increasingly important as the population ages and the prevalence of both conditions rises.

This guide walks through what cardiorenal syndrome is, the recognised subtypes, why integrated care matters, and what modern treatment can offer.

The term cardiorenal syndrome was formalised in 2008 by a consensus conference. The aim was to provide a structured way to describe the interactions between heart and kidney disease so that research, treatment, and conversation could be more precise. Five subtypes are recognised, based on which organ deteriorated first and over what timescale.

Type 1 is acute cardiorenal syndrome. Acute worsening of heart function causes acute kidney injury. The classical example is acute decompensated heart failure, in which the heart’s pumping function deteriorates and triggers a fall in kidney function. The mechanism involves reduced cardiac output, congestion of the kidney veins from fluid overload, neurohormonal activation, and the effects of medications used to treat the heart failure. The kidney function typically improves as the heart failure is managed, but the episode of AKI is itself associated with worse long-term outcomes.

Type 2 is chronic cardiorenal syndrome. Chronic heart failure causes progressive chronic kidney disease over years. This is the most common pattern in older patients with longstanding cardiovascular disease. The kidneys are damaged by chronic low cardiac output, chronic venous congestion, the cumulative effects of medications, and the systemic inflammation associated with heart failure. The decline in kidney function tends to mirror the severity and duration of the heart failure.

Type 3 is acute renocardiac syndrome. Acute kidney injury causes acute heart problems, including arrhythmias, ischaemia, and acute heart failure. The mechanisms include the metabolic and electrolyte disturbances of AKI, the fluid overload that often accompanies it, the inflammation, and the effects of any treatments such as dialysis. Patients with severe AKI have substantially higher rates of cardiac events than would be expected from their baseline cardiac risk alone.

Type 4 is chronic renocardiac syndrome. Chronic kidney disease contributes to chronic cardiovascular disease. Patients with advanced CKD have a high prevalence of left ventricular hypertrophy, heart failure, and ischaemic heart disease. The causes include chronic hypertension, anaemia, calcium and phosphate disturbances, chronic inflammation, accelerated atherosclerosis, and the effects of the uraemic environment on the heart muscle. Patients with CKD are far more likely to die from cardiovascular disease than from anything else, including from kidney failure itself.

Type 5 is secondary cardiorenal syndrome. Both heart and kidney are damaged by the same systemic process. Examples include sepsis (which damages both organs simultaneously), amyloidosis (which deposits in both heart and kidney), and autoimmune diseases such as lupus that affect multiple organ systems. The two organs are not causing each other’s damage but are both affected by the same underlying disease.

In practice, many patients have features of more than one subtype. An older patient with chronic heart failure and CKD (type 2 or 4) may have an episode of acute decompensation that produces AKI (type 1). The classification is useful for clinical reasoning but the categories are not always crisp in individual patients.

The practical challenge in cardiorenal syndrome is that many treatments for one organ can worsen the other. Diuretics relieve symptoms of heart failure by removing excess fluid, but they can worsen kidney function if used too aggressively. ACE inhibitors and angiotensin receptor blockers protect both heart and kidney over the long term, but they can cause acute kidney injury or hyperkalaemia during episodes of illness. Beta blockers benefit heart failure but can rarely worsen heart failure if introduced incorrectly. Spironolactone benefits both but raises the risk of high potassium. Each medication choice involves weighing benefit and risk across both organ systems.

The arrival of newer therapies has changed the picture substantially. SGLT2 inhibitors (empagliflozin, dapagliflozin) have shown benefits across the spectrum of cardiorenal disease. In heart failure, they reduce hospitalisation and cardiovascular death regardless of ejection fraction or diabetes status. In CKD, they slow the rate of kidney function decline. They appear to work through mechanisms beyond glucose lowering, including effects on kidney filtration pressure, fluid handling, and cellular metabolism. They are now standard care for most patients with heart failure or proteinuric CKD, with or without diabetes.

Sacubitril-valsartan (a combination of an angiotensin receptor blocker and a neprilysin inhibitor) has shown substantial benefits in heart failure with reduced ejection fraction and is increasingly used in patients with concurrent CKD. The PARADIGM-HF trial established the cardiac benefit. Subsequent studies have shown that the medication can be used safely in CKD with appropriate monitoring.

Finerenone, a newer mineralocorticoid receptor antagonist, has shown benefits in patients with type 2 diabetes and chronic kidney disease, with both kidney and cardiovascular endpoints improved in the FIDELIO-DKD and FIGARO-DKD trials. It is increasingly added to combinations including ACE inhibitor or ARB and SGLT2 inhibitor.

The modern treatment of cardiorenal syndrome therefore typically involves several layers: an ACE inhibitor or ARB (or sacubitril-valsartan in selected cases), an SGLT2 inhibitor, a mineralocorticoid receptor antagonist (spironolactone in heart failure, finerenone in diabetic CKD), and diuretics adjusted to maintain fluid balance. The combination produces additive benefits across heart and kidney outcomes.

What does integrated care look like in practice? It typically involves close collaboration between cardiology, nephrology, and primary care. Joint clinics exist in some centres. Shared protocols and shared electronic records help. Regular communication between specialists ensures that medication changes account for both organ systems. Patients benefit from a clear care plan that names who is responsible for what, how often each issue is reviewed, and what to do if any acute change occurs.

For patients, the practical implications include several things. Daily weight monitoring at home is one of the most useful tools, since fluid balance is at the centre of so much of the management. A sustained weight gain of 2 kg over a few days, or 1 kg in a day, often signals fluid retention and warrants attention. Sick day rules apply: during episodes of vomiting, diarrhoea, fever, or significantly reduced fluid intake, diuretics, ACE inhibitors, and ARBs are often best paused temporarily, with the doctor contacted for advice. NSAIDs should be avoided as a class. Salt intake should be moderate. Adequate but not excessive fluid intake should be maintained.

Electrolytes need monitoring. Potassium is the most common issue, particularly with the combination of ACE inhibitor or ARB plus mineralocorticoid receptor antagonist. Periodic blood tests are essential. Patients should be alert to symptoms of high potassium such as weakness, palpitations, or numbness, although mild high potassium is often asymptomatic.

The outlook for patients with cardiorenal syndrome has improved substantially over the last decade. The combination of better medications, more attention to integrated care, and better outpatient management has reduced hospitalisations and improved quality of life for many. Long-term outcomes remain challenging, particularly in patients with severe forms, but the picture is more positive than it was even a few years ago.

I see private patients at Blackrock Clinic, The Beacon Hospital, Bon Secours Dublin, the Hermitage Medical Centre, and St Vincent’s Private Hospital. If you would like a consultation about your kidney health, you or your GP can contact my secretary through drrorymcquillan.ie. Most patients are seen within two to three weeks of referral.